QNRX QUOIN PHARMACEUTICALS LTD revenue, earnings and financials
For the quarter ended June 30, 2026, QUOIN PHARMACEUTICALS LTD reported revenue of n/a, net income of −$5.37M and diluted EPS of n/a; for the fiscal year ended December 2025 revenue was n/a.
QNRX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income n/a, net income −$15.8M (margin n/a), EPS n/a
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income n/a, net income −$9.00M (margin n/a), EPS n/a
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income n/a, net income −$8.70M (margin n/a), EPS n/a
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income n/a, net income −$9.38M (margin n/a), EPS n/a
- Fiscal year ended Dec 2021: revenue $0, gross profit n/a, operating income n/a, net income −$21.5M (margin n/a), EPS −$0.01
QNRX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$5.37M, EPS n/a
- Quarter ended Mar 31, 2026: revenue n/a, net income −$5.00M, EPS n/a
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$4.34M, EPS n/a
- Quarter ended Sep 30, 2025: revenue n/a, net income −$3.95M, EPS n/a
- Quarter ended Jun 30, 2025: revenue n/a, net income −$3.70M, EPS n/a
- Quarter ended Mar 31, 2025: revenue n/a, net income −$3.81M, EPS n/a
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$2.35M, EPS n/a
- Quarter ended Sep 30, 2024: revenue n/a, net income −$2.35M, EPS n/a
- Quarter ended Jun 30, 2024: revenue n/a, net income −$1.97M, EPS n/a
- Quarter ended Mar 31, 2024: revenue n/a, net income −$2.33M, EPS n/a
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$2.06M, EPS n/a
- Quarter ended Sep 30, 2023: revenue n/a, net income −$1.93M, EPS n/a
- Quarter ended Jun 30, 2023: revenue n/a, net income −$2.11M, EPS n/a
- Quarter ended Mar 31, 2023: revenue n/a, net income −$2.60M, EPS n/a
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$2.00M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$3.03M, EPS n/a
- Quarter ended Jun 30, 2022: revenue n/a, net income −$2.67M, EPS n/a
- Quarter ended Mar 31, 2022: revenue n/a, net income −$1.68M, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$11.8M, EPS n/a
- Quarter ended Sep 30, 2021: revenue n/a, net income −$1.40M, EPS n/a
QNRX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$13.5M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$7.86M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$7.86M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$8.48M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$5.72M, share buybacks n/a
QNRX balance sheet
- Jun 30, 2026: cash $3.85M, total assets $12.0M, total liabilities $8.04M, shareholders' equity $3.93M
- Mar 31, 2026: cash $3.12M, total assets $15.7M, total liabilities $6.92M, shareholders' equity $8.77M
- Dec 31, 2025: cash $3.82M, total assets $20.4M, total liabilities $7.27M, shareholders' equity $13.1M
- Sep 30, 2025: cash $1.83M, total assets $6.42M, total liabilities $7.64M, shareholders' equity −$1.21M
- Jun 30, 2025: cash $1.67M, total assets $8.91M, total liabilities $6.36M, shareholders' equity $2.55M
- Mar 31, 2025: cash $3.82M, total assets $13.0M, total liabilities $7.03M, shareholders' equity $5.93M
- Dec 31, 2024: cash $3.62M, total assets $15.7M, total liabilities $6.50M, shareholders' equity $9.20M
- Sep 30, 2024: cash $3.12M, total assets $11.4M, total liabilities $5.95M, shareholders' equity $5.44M
Is QNRX profitable?
No. QUOIN PHARMACEUTICALS LTD lost $18.7M over the last four quarters.